Gilead Sciences (GILD) Research & Development (2009 - 2026)

Gilead Sciences (GILD) has reported Research & Development for 18 consecutive years, with $1.8 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Research & Development rose 18.31% year-over-year to $1.8 billion; the trailing twelve-month figure through Jun 2026 stood at $6.1 billion (up 2.71% YoY), and the FY2025 full-year result was $5.8 billion, down 1.83% from the prior year.
• Research & Development climbed to $1.8 billion in Q2 2026 per GILD's latest filing, from $1.4 billion in the prior quarter.
• Across five years, Research & Development topped out at $1.8 billion in Q2 2026 and bottomed at $1.1 billion in Q2 2022.
• Historically, Research & Development has averaged $1.4 billion across 5 years, with a median of $1.4 billion in 2023.
• The sharpest annual moves came in 2023 and 2025: Research & Development gained 27.68% in 2023, then slipped 9.28% in 2025.
• Over 5 years, Research & Development stood at $1.5 billion in 2022, then declined by 9.04% to $1.4 billion in 2023, then increased by 16.55% to $1.6 billion in 2024, then declined by 3.47% to $1.6 billion in 2025, then grew by 11.36% to $1.8 billion in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $1.8 billion, $1.4 billion, and $1.6 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.